CN114699528A - 用于表达pde3a或slfn12的癌症的组合物和方法 - Google Patents

用于表达pde3a或slfn12的癌症的组合物和方法 Download PDF

Info

Publication number
CN114699528A
CN114699528A CN202210036941.5A CN202210036941A CN114699528A CN 114699528 A CN114699528 A CN 114699528A CN 202210036941 A CN202210036941 A CN 202210036941A CN 114699528 A CN114699528 A CN 114699528A
Authority
CN
China
Prior art keywords
pde3a
cancer
dnmdp
slfn12
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210036941.5A
Other languages
English (en)
Chinese (zh)
Inventor
L.德瓦尔
M.迈耶森
H.格罗伊利希
M.舍诺恩
A.伯金
X.吴
U.萨克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Dana Farber Cancer Institute Inc
Broad Institute
Original Assignee
Bayer Pharma AG
Dana Farber Cancer Institute Inc
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Dana Farber Cancer Institute Inc, Broad Institute filed Critical Bayer Pharma AG
Publication of CN114699528A publication Critical patent/CN114699528A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202210036941.5A 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法 Pending CN114699528A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562204875P 2015-08-13 2015-08-13
US62/204,875 2015-08-13
CN201680059256.7A CN108366947B (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法
PCT/US2016/046912 WO2017027854A1 (en) 2015-08-13 2016-08-12 Compositions and methods for cancer expressing pde3a or slfn12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680059256.7A Division CN108366947B (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法

Publications (1)

Publication Number Publication Date
CN114699528A true CN114699528A (zh) 2022-07-05

Family

ID=57983814

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210036941.5A Pending CN114699528A (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法
CN201680059256.7A Active CN108366947B (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680059256.7A Active CN108366947B (zh) 2015-08-13 2016-08-12 用于表达pde3a或slfn12的癌症的组合物和方法

Country Status (6)

Country Link
US (2) US11207320B2 (cg-RX-API-DMAC7.html)
EP (1) EP3334404B1 (cg-RX-API-DMAC7.html)
JP (2) JP6968054B2 (cg-RX-API-DMAC7.html)
CN (2) CN114699528A (cg-RX-API-DMAC7.html)
CA (1) CA2995375C (cg-RX-API-DMAC7.html)
WO (1) WO2017027854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201733591A (zh) 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
CN107312824A (zh) * 2016-04-26 2017-11-03 中国科学院上海药物研究所 Pde3a在判断阿那格雷治疗肿瘤效果中的应用
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
TW202031677A (zh) 2018-11-01 2020-09-01 美商博得學院股份有限公司 Pde3調節劑反應性癌症之鑑定
AU2020215088A1 (en) 2019-02-01 2021-07-22 Bayer Aktiengesellschaft 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases
CN112402613A (zh) * 2019-08-23 2021-02-26 中国科学院上海药物研究所 Pde3抑制剂与细胞因子联合治疗肿瘤的应用
CN117279644A (zh) * 2021-03-03 2023-12-22 拜耳股份有限公司 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮
CN117062819B (zh) * 2021-03-23 2026-07-17 北京生命科学研究所 多环化合物及其用途
CN114814221A (zh) * 2022-02-24 2022-07-29 中南大学湘雅医院 一种甲状腺癌早期诊断标志物及其应用
CN116705196B (zh) * 2023-06-28 2025-08-19 湖南师范大学 基于符号图神经网络的药物靶标互作用预测方法及装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4092311A (en) 1976-06-03 1978-05-30 American Cyanamid Company Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
JPS6061570A (ja) 1983-09-16 1985-04-09 Sankyo Co Ltd ピリダジノン誘導体及び農業用殺菌剤
US5053338A (en) 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
JPH05140116A (ja) 1991-11-21 1993-06-08 Nippon Soda Co Ltd 光学活性な化合物
CA2204915A1 (en) 1994-11-11 1996-05-23 Seiichi Uchida Optically active compound
WO2003001968A2 (en) * 2001-06-26 2003-01-09 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
CA2782620A1 (en) * 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
JP6445573B2 (ja) * 2013-10-17 2018-12-26 サルタル セラピューティクス エルティーディSartar Therapeutics Ltd ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
JP5852759B1 (ja) * 2015-04-01 2016-02-03 株式会社キュービクス 遺伝子発現解析による膵臓癌の検出
TW201733591A (zh) 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
US11142522B2 (en) * 2017-02-03 2021-10-12 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
TW202031677A (zh) * 2018-11-01 2020-09-01 美商博得學院股份有限公司 Pde3調節劑反應性癌症之鑑定

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer

Also Published As

Publication number Publication date
JP2018531892A (ja) 2018-11-01
JP6968054B2 (ja) 2021-11-17
WO2017027854A1 (en) 2017-02-16
CN108366947B (zh) 2022-03-29
CN108366947A (zh) 2018-08-03
US11207320B2 (en) 2021-12-28
JP2021169488A (ja) 2021-10-28
EP3334404A4 (en) 2019-02-13
CA2995375A1 (en) 2017-02-16
EP3334404A1 (en) 2018-06-20
CA2995375C (en) 2024-06-18
EP3334404B1 (en) 2024-09-18
US20180235961A1 (en) 2018-08-23
US20220071995A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CN108366947B (zh) 用于表达pde3a或slfn12的癌症的组合物和方法
CN108883112B (zh) 用于癌症患者分级和癌症治疗的化合物、组合物和方法
Brenke et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity
KR102511807B1 (ko) 인간 ezh2의 억제제 및 이의 사용 방법
Zhou et al. Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D
US10125135B2 (en) Chemical compounds
WO2017080980A1 (en) Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
JP2022504541A (ja) 低分子mdm2タンパク質デグレーダー
TW201636344A (zh) Ezh2抑制劑
JP2021072776A (ja) Ttk阻害剤化学療法の為の予後バイオマーカー
TW202202143A (zh) 使用cdk4/6及cdk2抑制劑共同治療以遏止腫瘤對cdk2抑制劑之適應性
Kruewel et al. Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers
Carbone et al. Novel Pyrazolo [1, 5‐a]− 1, 3, 5‐Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models
Bacci et al. Ribosomal protein L5 (RPL5/uL18) I60V mutation is associated to increased translation and modulates drug sensitivity in T-cell acute lymphoblastic leukemia cells
US10851051B2 (en) Compositions and methods for treating multiple myeloma
WO2024089190A1 (en) Prune1 inhibitors and therapeutic use thereof
Cheung et al. Finding a Needle in a Haystack. Identification of Tankyrase, a Novel Therapeutic Target of the Wnt Pathway Using Chemical Genetics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination